Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients.
Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension. Even as beta-adrenergic agonists find increasing use in the therapy of acute hyperkalemia, physicians should be aware of the potential of beta blockers to cause profound elevations of serum potassium.